2d • General discussion
Friday Performance Challenge
💪 Friday Performance Challenge: Stop Trying to Have the “Perfect” Fitness Week
This weekend’s challenge is simple:
Accumulate 60 minutes of intentional movement between Saturday and Sunday.
You can do it all at once or break it up:
- 30-minute strength session + 30-minute walk
- Two 30-minute walks
- 20 minutes Saturday + 40 minutes Sunday
- Hike, bike, swim, lift, run—pick something you’ll actually do
Why we’re doing this
A lot of women fall into the “I missed Monday, so this week is ruined” mindset.
The research doesn’t support that thinking.
Large observational studies have found that people who accumulate recommended amounts of moderate-to-vigorous physical activity in only 1–2 days per week can still experience substantial health benefits. A 2025 study using activity trackers found lower all-cause, cardiovascular and cancer mortality among both “weekend warriors” and people who spread activity throughout the week.
A previous cohort of more than 350,000 adults—about 51% women— similarly found no significant mortality difference between people concentrating their activity into 1–2 sessions and those exercising ≥3 times per week when total weekly activity was comparable.
Important: these studies are observational. They don’t prove that cramming exercise into the weekend is better, and they don’t tell us the ideal training schedule for muscle growth or athletic performance.
They tell us something more practical:
A disrupted week doesn’t have to become an abandoned week.
🐐 GOATGETheR Take
Your health doesn’t reset because you missed Tuesday.
Consistency should be measured over months and years, not by whether every seven-day period looked perfect.
Get your 60 minutes this weekend and drop a DONE below when you’ve finished.
🧬 Friday Peptide Spotlight: Retatrutide — What Do We Actually Know Now?
Retatrutide deserves a spotlight because the conversation around it is moving much faster than most people’s understanding of the evidence.
First: what is it?
Retatrutide is a single investigational molecule designed to activate three receptors:
GIP + GLP-1 + glucagon.
Think of these as three different metabolic signaling pathways being targeted simultaneously.
The strongest peer-reviewed evidence
In the published Phase 2 randomized, double-blind trial, 338 adults with obesity or overweight plus a weight-related condition received different doses of retatrutide or placebo.
After 48 weeks, average weight change reached:
1 mg: −8.7%
4 mg: −17.1%
8 mg: −22.8%
12 mg: −24.2%
Placebo: −2.1%
Interestingly, a prespecified exploratory analysis found greater percentage weight reductions among female participants than male participants. That’s interesting, but it isn’t enough to conclude that retatrutide inherently works better in women. The trial wasn’t designed primarily to answer that question.
What about side effects?
The most common adverse events were gastrointestinal and generally increased with dose. Researchers also observed dose-dependent increases in heart rate that peaked around week 24 before declining.
🚨 And here’s the part social media often leaves out
As of August 2026, retatrutide is still investigational and is not approved by any regulatory agency.
Phase 3 research is underway, and Lilly announced positive topline results from several Phase 3 trials this year. For example, the company reported average weight loss of up to 28.3% at 80 weeks in TRIUMPH-1. But those topline results should not be treated the same as a complete peer-reviewed publication that researchers can independently examine.
That’s an important distinction we will make consistently inside GOATGETheR:
Promising ≠ proven.
Clinical trial drug ≠ approved medication.
Research chemical sold online ≠ pharmaceutical product used in the clinical trial.
Lilly specifically states that products currently being sold outside its clinical trials claiming to be retatrutide are not approved retatrutide products and may have uncertain ingredients, purity or dosing.
Evidence Confidence
Weight-loss efficacy in controlled human research: HIGH
Long-term safety: STILL DEVELOPING
Female-specific effects: LOW/INSUFFICIENT
Claims about athletic performance, muscle building or longevity: INSUFFICIENT HUMAN EVIDENCE
Unregulated/research-market products being equivalent to trial retatrutide: NOT ESTABLISHED
🐐 GOATGETheR Take
Retatrutide is legitimately exciting science.
That’s exactly why we don’t need to exaggerate it.
We can watch the research evolve while being clear about what researchers know, what they don’t know, and what social media has filled in on its own.
🔎 Bobbie’s N=1 Experience
I’ll also document my personal experience separately from the research.
That distinction matters:
Clinical research asks: What tends to happen across groups of people under controlled conditions?
My experience asks: What happened to one person?
One can help us understand the other, but my results can never prove that retatrutide caused an effect or predict what another woman will experience.
We’ll track things such as appetite, food intake, training, energy, recovery, body weight/body composition where available, GI effects and other noticeable changes over time.
Sources
The primary retatrutide paper is the 2023 Phase 2 randomized trial published in the New England Journal of Medicine.
Read the full NEJM retatrutide study
For current development status, Lilly’s July 2026 update confirms that retatrutide remains investigational and summarizes the ongoing Phase 3 program.
Current retatrutide clinical-development status
For the Performance Challenge, the supporting physical-activity research is available through PubMed — 2025 device-measured weekend-warrior study and PubMed — 350,978-person cohort study.
1
2 comments
Friday Performance Challenge
powered by
skool.com/goatgether-3744
Evidence-based women’s health, fitness & performance. Research simplified. Build confidence, strength & become a founding member.
Suggested communities
Powered by